Brochure
Neurodegenerative disorders are complex, highly heterogeneous and complicated by co-pathologies. Historically, these challenges have limited progress in the diagnosis and treatment of CNS diseases but the recent emergence of highly sensitive assays to measure blood- based biomarkers is transforming the field.
These advancements are giving renewed hope to researchers and patients alike with the promise of earlier detection, personalized treatment plans and improved patient outcomes across a spectrum of CNS related disorders.
Given the heterogeneous pathology of AD and mixed dementia, inflammation, synaptic, and vascular markers can play a key role in understanding disease pathophysiology. By measuring multiple CNS proteins simultaneously, Alamar’s ultra-sensitive NULISA™ multiplex panels can monitor changes across key processes to provide insights beyond the established AT(N) biomarkers. Karikari, et al. demonstrates how multiplexed, blood-based profiling can provide a comprehensive view of AD-associated proteomic changes, consistent with the recently revised biological and diagnostic framework.
PD, PDD and DLB are conditions that all sit on the Lewy body disease spectrum, driven by abnormal aggregation of α-synuclein in the brain, but they differ in timing and clinical presentation. By the time PD or DLB is clinically diagnosed, significant neuronal loss has already occurred and available treatments are only symptomatic and offer diminishing benefits over time. Developing a reliable PD risk score based on molecular biomarkers opens up the potential for disease modifying therapies that could delay or halt disease onset.
Improving ALS outcomes is challenging due to disease complexity and heterogeneity. Plasma-based biomarkers, especially NFL, correlate with axon loss, disease progression, and disease conversion risk in mutation carriers like those with SOD1 variants. Additional biomarkers are needed to identify disease stages, track co-pathologies, and monitor therapy, complementing NFL measurements.
The pathology and outcomes of traumatic brain injury (TBI) are complex and varied, and existing diagnostic methods have limited ability to assess the underlying pathology. Proteomic techniques that use fluid-based biomarkers offer a valuable solution, as they allow for sensitive and thorough evaluation of all processes that may be related to TBI pathophysiology.
MS is a chronic, immune-mediated disorder of the central nervous system characterized by inflammation, demyelination, and neurodegeneration. In recent years, advances in biomarker testing have transformed the landscape of MS research with fluid-based proteomic assays provide a promising avenue for uncovering the complex nature of the disease.